Trials / Completed
CompletedNCT00623558
Cetuximab as Induction Treatment in Head and Neck Squamous Cell Carcinoma (HNSCC)
A Randomized, Multicenter, Open Phase II Study of Cetuximab With Docetaxel, Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 92 (actual)
- Sponsor
- Seoul National University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the study is to investigate the efficacy and safety of cetuximab, docetaxel, cisplatin combination as induction therapy in locally advanced head and neck squamous cell carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cetuximab | 400 mg/m2 first dose, then 250 mg/m2 weekly for 9 weeks |
| DRUG | Docetaxel | 75 mg/m2, day 1 of every 3 weeks for 9 weeks (3 cycles) |
| DRUG | Cisplatin | 75 mg/m2, day 1 of every 3 weeks for 9 weeks (3 cycles) |
Timeline
- Start date
- 2008-04-01
- Primary completion
- 2012-11-01
- Completion
- 2013-08-01
- First posted
- 2008-02-26
- Last updated
- 2013-12-04
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT00623558. Inclusion in this directory is not an endorsement.